Drugs / SAR443216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05013554 | Aug 2021 → Jan 2024 | breast cancer, gastric cancer, lung cancer | Sanofi | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR443216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05013554 ↗ |
| Route | Intravenous | “Route of administration: IV infusion” NCT05013554 ↗ |